SAN DIEGO, Nov. 14, 2011 /PRNewswire/ -- Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the appointment of Dr. Peter Heseltine as Senior Vice President and Chief Medical Officer.
Dr. Heseltine joins Prometheus with almost 35 years of experience in the medical field. He comes most recently from Beckman Coulter where he served as Vice President and Medical Director of Global Businesses since 2005. In this role he had corporate responsibility for medical input and oversight of in vitro diagnostics product design, development and life cycle management, including new cancer diagnostics, using immunoassay, flow cytometry and molecular technologies.
Prior to joining Beckman Coulter, Dr. Heseltine was Medical Director of Infectious Diseases at Nichols Institute Quest Diagnostics supervising high-volume, Molecular, Microbiology, Virology and Serology clinical laboratories. He formed a team of research scientists to develop new esoteric tests for infectious diseases under ISO 9001 standards and led a Six Sigma quality improvement program that introduced more than 50 new tests in four years. Prior to joining Quest Diagnostics, Dr. Heseltine was a Chief Physician at Los Angeles County USC Hospital and Professor of Medicine at the University of Southern California. Dr. Heseltine received his medical training at Trinity College, Dublin University and postgraduate training at Yale University, the University of California, Los Angeles and the U. S. Centers for Disease Control. He is Board certified in Internal Medicine and Infectious Diseases. Dr. Heseltine is a Fellow of the American College of Physicians, Fellow of the National Academy of Clinical Biochemistry and a Fellow of the Infectious Diseases Society of America. He maintains a position as Clinical Professor of Medicine at the University of California, Irvine.
"Peter brings a wealth of medical, clinical and product development experience which will be very valuable during this important stage of our company's growth," said Joseph M. Limber, President and Chief Executive Officer of Prometheus. "He is a welcome addition to our senior management team and will play a key role in planning and executing our core strategy as we continue to build on our success."
Prometheus Laboratories Inc. is committed to improving lives through the development and commercialization of novel pharmaceutical and diagnostic products that enable physicians to provide greater individualized patient care. Prometheus is a leader in applying the principles of personalized medicine to the diagnosis and treatment of gastrointestinal diseases and is applying these principles to oncology. Its strategy includes the marketing and delivery of pharmaceutical products complemented by proprietary diagnostic testing services. By integrating therapeutics and diagnostics, Prometheus believes it can provide physicians with more targeted solutions to optimize care for their patients. Prometheus became part of Nestle Health Science in July 2011. Prometheus' corporate offices are located in San Diego, California. For more information about Prometheus, please visit www.prometheuslabs.com.
About Nestle Health Science
Nestle Health Science, a fully-owned subsidiary of Nestle S.A., is operational since January 1, 2011 and has worldwide headquarters in Lutry, Switzerland. Nestle Health Science offers nutritional solutions for people with specific dietary needs related to illnesses, disease states or the special challenges of different life stages. For more information about Nestle Health Science, please visit www.nestlehealthscience.com.
SOURCE Prometheus Laboratories Inc.